Novartis AG (NVS): Price and Financial Metrics

Novartis AG (NVS)

Today's Latest Price: $87.05 USD

0.06 (-0.07%)

Updated Sep 28 7:00pm

Add NVS to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 239 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

NVS Stock Summary

  • NVS has a market capitalization of $197,304,889,390 -- more than approximately 99.3% of US stocks.
  • The volatility of Novartis Ag's share price is greater than that of only 1.02% US stocks with at least 200 days of trading history.
  • Novartis Ag's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 8.58%, greater than the shareholder yield of 78.87% of stocks in our set.
  • Stocks that are quantitatively similar to NVS, based on their financial statements, market capitalization, and price volatility, are PFE, MRK, SAP, NVO, and NFLX.
  • Visit NVS's SEC page to see the company's official filings. To visit the company's web site, go to
NVS Daily Price Range
NVS 52-Week Price Range

NVS Stock Price Chart Technical Analysis Charts

NVS Price/Volume Stats

Current price $87.05 52-week high $99.84
Prev. close $87.11 52-week low $69.18
Day low $86.99 Volume 1,011,240
Day high $87.74 Avg. volume 2,150,359
50-day MA $86.39 Dividend yield 2.31%
200-day MA $87.82 Market Cap 199.23B

Novartis AG (NVS) Company Bio

Novartis AG offers patented prescription medicines in various therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience, and established medicines. The company was founded in 1895 and is based in Basel, Switzerland.

NVS Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$87.05$58.92 -32%

We started the process of determining a valid price forecast for Novartis Ag with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Novartis Ag ranked in the 35th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Novartis Ag, consider:

  • The compound growth rate in the free cash flow of Novartis Ag over the past 5.01 years is 0.03%; that's higher than only 23.37% of free cash flow generating stocks in the Healthcare sector.
  • NVS's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 32.16% of tickers in our DCF set.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

EDAP, BDX, IQV, ITGR, and GILD can be thought of as valuation peers to NVS, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.

NVS Latest News Stream

Event/Time News Detail
Loading, please wait...

NVS Latest Social Stream

Loading social stream, please wait...

View Full NVS Social Stream

Latest NVS News From Around the Web

Below are the latest news stories about Novartis Ag that investors may wish to consider to help them evaluate NVS as an investment opportunity.

Novartis Agrees $678 Million Kickbacks Settlement With 26 U.S. States - NYAG

Novartis has agreed to pay around $680 million to 26 U.S. states liked to allegations of 'kick-backs' to healthcare providers to encourage them to prescribe the Swiss drugmaker's products.

The Street | September 25, 2020

Patient Investors Will Stick With Very Cheap Bristol-Myers Squibb Stock

Bristol-Myers Squibb (NYSE:BMY) is incredibly cheap. For example, based on earnings estimates, BMY stock trades at just 7.8 times next year's earnings.Source: IgorGolovniov / In addition, it has an attractive dividend yield of 3.11%, which is likely to increase soon. I estimate the stock is worth at least $84.47, or 46% more than its present price.And that is after discounting its real worth significantly, to add in a margin of safety. The target price is primarily based on its expected earnings and dividends, its history, and comparisons with its peers.InvestorPlace - Stock Market News, Stock Advice & Trading Tips BMY Stock Earnings and Dividend ExpectationsLast quarter, the company blew away analysts' earnings forecasts. It is likely to do so again this quarte...

Yahoo | September 25, 2020

Novartis Provides Update on AVXS-101 Intrathecal Clinical Development Program

* Novartis Gene Therapies to initiate new pivotal confirmatory study to evaluate use of AVXS-101 intrathecal (IT) formulation in older patients with SMA to further support registration Basel, September 23, 2020 – Novartis Gene Therapies recently received feedback from the US Food and Drug Administration (FDA) following their review of data from the STRONG study of the intrathecal (IT) formulation of AVXS-101 in older patients with spinal muscular atrophy (SMA). The FDA has acknowledged the potential of AVXS-101 IT in this patient population and recommends a pivotal confirmatory study to supplement the existing STRONG data and further support the regulatory submission for AVXS-101 IT.This guidance provides clarity on the path to registration for AVXS-101 IT. Trial design and other detai...

Yahoo | September 23, 2020

Siemens Healthineers Announces Collaboration Agreement for Assay Development With an Initial Focus on Multiple Sclerosis

BERKELEY, Calif.--(BUSINESS WIRE)--Siemens Healthineers announced today a master collaboration agreement with Novartis Pharma AG to design, develop, and commercialize diagnostic tests for therapeutic products across Novartis’ therapeutic pipeline. The initial program assists the development of a serum NfL immunoassay to support Novartis’ MS and other neuroscience programs. NfL is a highly specific biomarker for nerve cell injury measured in cerebral spinal fluid and blood. Blood NfL levels have

Business Wire | September 21, 2020

Novartis Announces Data on Tafinlar, Mekinist & Piqray at ESMO

Novartis (NVS) announces data from late-stage studies on Tafinlar, Mekinist and Piqray at ESMO 2020.

Yahoo | September 21, 2020

Read More 'NVS' Stories Here

NVS Price Returns

1-mo 0.52%
3-mo -0.33%
6-mo 7.56%
1-year 1.96%
3-year 24.84%
5-year 24.11%
YTD -5.89%
2019 28.03%
2018 5.95%
2017 18.80%
2016 -12.56%
2015 -4.52%

NVS Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full NVS Dividend History

Continue Researching NVS

Want to see what other sources are saying about Novartis Ag's financials and stock price? Try the links below:

Novartis Ag (NVS) Stock Price | Nasdaq
Novartis Ag (NVS) Stock Quote, History and News - Yahoo Finance
Novartis Ag (NVS) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.8805 seconds.